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the first-line treatment for advanced PCa to suppress 
androgen action. Most patients respond to this treat-
ment initially; however, the PCa eventually becomes 
castration-resistant, and is then often subsequently le-
thal. Nevertheless, even in this castration-resistant 
state, androgen and the androgen receptor (AR) remain 
Introduction
　Prostate cancer (PCa) is one of the leading causes of 
death from cancer in males in Western countries and is 
the sixth most common cause of cancer mortality in 
Japanese males.1) PCa is initially androgen dependent, 
and castration (androgen deprivation therapy, ADT) is 
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Abstract
　Prostate cancer is initially androgen dependent, and androgen deprivation therapy is the first-line 
treatment for advanced disease. Most patients respond to castration; however, tumors eventually be-
come castration-resistant prostate cancer (CRPC). Nevertheless, androgen and the androgen receptor 
(AR) remain active, and affect the progression of CRPC. More effective androgen suppression or 
AR-targeted therapies can be useful to treat such patients. The mechanisms underlying the develop-
ment of CRPC include AR hypersensitivity, intra-tumoral androgen synthesis, changes in AR ligand 
specificity due to mutations, ligand-independent AR activation, pathway(s) bypassing the AR and the 
proliferation of androgen-independent tumor cells. Historically, the primary endpoint of CRPC treat-
ment has been palliation. In 2004, docetaxel became the first chemotherapeutic agent to demonstrate 
a significant survival benefit. In 2010, cabazitaxel was proven to prolong survival after docetaxel resis-
tance. Also in 2010, Sipuleucel-T was approved as a cell-based cancer immunotherapy, and an adrenal 
androgen inhibitor, abiraterone acetate, was revealed to prolong the survival of patients with CRPC. 
In 2013, a second-generation anti-androgen, enzalutamide, was shown to improve the survival of CRPC 
patients, and radium-223, a bone-targeted agent, was approved for CRPC. Determining how to apply 
these new agents for each patient in clinical practice is an important issue.
和文要旨
　前立腺癌はアンドロゲン依存癌である。内分泌療法を施行した場合当初は治療に奏功するが，次第に
治療抵抗性となる。この機序には，腫瘍のアンドロゲン産生，アンドロゲン受容体（AR）増幅，ARの
リガンド特異性の喪失，ARを介さない経路などがある。多くでARを介した増殖経路が残っていて去勢
状態でも増殖に関与しており，去勢抵抗性前立腺癌と呼ぶ。去勢抵抗性前立腺癌に対する治療は従来緩
和目的のみであったが，2004年にタキサン系の抗がん剤であるドセタキセルで生存期間延長効果が初め
て示された。その後，タキサン系の薬剤としてカバジタキセル，免疫治療としてシプルーセルT，副腎
性アンドロゲン産生抑制剤であるアビラテロン，第２世代抗アンドロゲン剤であるエンザルタミド，放
射線同位元素であるRa-223で予後改善効果が認められている。今後これらの薬剤を実際の症例にどのよ
うに使用していくかが大きな課題である。
Key words: androgen, androgen-independent prostate cancer, androgen receptor, castration-resistant 
prostate cancer, hormone-refractory prostate cancer
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・Radiological progression: The appearance of two 
or more bone lesions on bone scan or enlargement of 
a soft tissue lesion using RECIST. 
　Observation of the response after anti-androgen with-
drawal or second- and third-line hormone therapies is 
important.9,10) However, no associated survival benefit 
has ever been reported for such treatments. In addition, 
the description of anti-androgen withdrawal is not in-
cluded in the latest CRPC definition from the EAU. A 
similar definition of PCa progression is included in the 
Prostate Cancer Working Group 2.11)
　In the General Rules for Clinical and Pathological 
Studies on Prostate Cancer (Japan), CRPC is defined as 
being present when clinical and/or PSA progression is 
found even if the serum testosterone level is maintained 
below 50 ng/dL either by surgical or medical castration, 
regardless of the use of anti-androgens.12) Therefore, it 
is necessary to keep in mind that the CRPC definition 
varies among studies, and may be changed in the fu-
ture.
II. The mechanisms underlying the development and 
progression of castration-resistant prostate cancer
　Scher et al. classified PCa based on its androgen-de-
pendency and hormone sensitivity according to the tu-
mor response to treatments under various situations.13) 
In this scheme, a tumor that is proliferating despite cas-
trate levels of testosterone, and that responds to addi-
tional hormonal manipulation is considered to be andro-
gen-independent but hormone-sensitive. A tumor that 
has not responded to sequential hormonal manipula-
tions is androgen-independent and hormone-insensitive. 
It is the latter tumors that are typically classified as 
hormone refractory. When a tumor can be called andro-
gen independent and hormone sensitive, a decrease in 
proliferation may be observed in response to adrenal 
androgen blockade, corticosteroids, anti-androgen with-
drawal or other hormonal manipulations.
　The potential mechanisms of the castration-resistant 
progression of PCa are summarized in Table 1.14,15) The 
key issue is that androgen and the androgen receptor 
are involved in most cases of CRPC; AR amplification is 
found in about 30% of cases and hyperactivated AR 
mutations are present in 20-40% of the patients with 
progression of PCa.16)
A. AR hypersensitivity
　Masai et al. reported that the percentage of strongly 
positive cancer cells of the prostate was inversely cor-
active in the progression of PCa. Therefore, the terms, 
“hormone-refractory prostate cancer” or “androgen-in-
dependent prostate cancer” are now thought to be inap-
propriate; castration-resistant prostate cancer (CRPC) is 
now being widely used instead, because more effective 
androgen suppression or AR-targeted therapies can 
still be used to treat such patients.2) The definition of 
CRPC, the mechanisms underlying its development and 
progression and the progress in the treatment of CRPC 
are reviewed in this article.
I. The definition of castration-resistant prostate cancer
　The precise definition of recurrent or relapsed PCa 
remains controversial. Several groups have published 
practical recommendations for defining CRPC. Howev-
er, the definition of castration-resistant progression has 
varied among studies3～5). In the guidelines on PCa 2012 
(also 2013) from the European Association of Urology 
(EAU), the definition is described as follows6) :
・Castrate serum levels of testosterone (testosterone 
< 50 ng/dL or < 1.7 nmol/L).
・Three consecutive rises of prostate specific antigen 
(PSA), 1 week apart, resulting in two 50% increases 
over the nadir, with a PSA > 2 ng/mL.
・Anti-androgen withdrawal for at least 4 weeks for 
flutamide and for at least 6 weeks for bicalutamide*
・PSA progression, despite consecutive hormonal 
manipulations†
* Either anti-androgen withdrawal or one secondary 
hormonal manipulation should have been done in 
order to fulfill the criteria for CRPC if patients have 
been treated with anti-androgens in the context of 
maximum androgen blockade or step up therapy fol-
lowing PSA progression after failure of luteinizing 
hormone-releasing hormone (LHRH) treatment.
†Progression of osseous lesions: progression or ap-
pearance of two or more lesions on bone scan or soft 
tissue lesions using RECIST (Response Evaluation 
Criteria in Solid Tumours), and with nodes > 2 cm in 
diameter.7)
These criteria indicate that PSA progression was the 
main condition required to define progression. In 2014, 
this definition was changed as follows8):
・Castrate serum testosterone < 50 ng/ml or 1.7 
nmol/L plus either: Biochemical progression: Three 
consecutive rises of PSA, 1 week apart, resulting in 
two 50% increases over the nadir, with PSA > 2 ng/
mL.
or
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gen concentration.
B. Intra-tumoral androgen synthesis
　When castration therapy is administered, either sur-
gically or with a LHRH agonist, it has been demonstrat-
ed that dihydrotestosterone (DHT) can still be detected 
in locally recurrent and metastatic prostate cancer tis-
sue at levels that are sufficient to activate the AR. The 
two dominant sources of androgens in males with CRPC 
are the adrenal androgens, dehydroepiandrosterone 
(DHEA) and DHEA-sulfate (DHEA-S), and de novo syn-
thesis by the prostate gland.22,23) Nishiyama et al. demon-
strated that the DHT levels in prostate tissue after 
ADT remained at approximately 25% of the amount 
measured before ADT. The DHT levels in serum de-
creased to approximately 7.5% after ADT. The level of 
DHT in prostatic tissue before ADT was not correlated 
with the serum level of testosterone. The serum levels 
of adrenal androgens were reduced to approximately 
60% after ADT. The source of DHT in prostatic tissue 
after ADT is thought to involve intracrine production 
within the prostate, wherein adrenal androgens are 
converted to DHT. Targeting the DHT still remaining 
in prostate tissue after ADT may require new thera-
pies to reduce intratumoral androgen synthesis.24) 
　Montgomery et al. reported that castration-resistant 
metastases displayed alterations in genes encoding ste-
roidogenic enzymes, including upregulated expression 
of FASN, CYP17A1, HSD3B1, HSD17B3, CYP19A1, and 
UGT2B17, and downregulated expression of SRD5A2 
(P<0.001 for all), compared with the levels in primary 
prostate tumors. Metastatic PCas from anorchid males 
were found to express transcripts encoding andro-
related with the grade. Relapsed cells showed a low 
population of strongly positive cells, irrespective of the 
grade. These findings mean that the AR still exists 
even in cells treated by androgen deprivation.17) In later 
studies, Visakorpi’s group reported AR amplification in 
hormone refractory PCa cells. Comparative genomic 
hybridization studies showed that amplification of the 
Xq11-q13 region (the location that encodes the AR), is 
common in tumors recurring during ADT. They found 
high-level AR amplification in seven of 23 (30%) recur-
rent tumors, but in none of the specimens taken from 
the same patients prior to therapy.18) Hormone-refracto-
ry tumors expressed the AR and showed, on average, 
six-fold higher expression than androgen-dependent tu-
mors or benign prostate hyperplasias (P<0.001). Four of 
13 (31%) hormone-refractory tumors contained AR gene 
amplification detected by fluorescence in situ hybrid-
ization. Androgen-independent tumors with gene ampli-
fication expressed, on average, a two-fold higher level of 
the AR than did the refractory tumors without the 
gene amplification.19) AR amplification can also be de-
tected in circulating tumor cells.20)
　Using microarray-based profiling of isogenic PCa xe-
nograft models, Chen et al. found that a modest increase 
in AR mRNA was the only change consistently associ-
ated with the development of resistance to anti-andro-
gen therapy. This increase in AR mRNA and protein 
expression was both necessary and sufficient to convert 
PCa growth from a hormone-sensitive to a hormone-re-
fractory stage, and was dependent on a functional li-
gand-binding domain.21) These findings indicated that 
AR amplification emerges during ADT by facilitating 
tumor cell growth in an environment with a low andro-
Table 1. Mechanisms underlying the development and progression of castration-resistant prostate cancer
Causes of castration-resistance
Androgen
dependence
AR-dependent
change
Mechanisms
a. AR hypersensitivity + + Amplification of AR ; abnormal expression of AR co-factors
b. Intra-tumoral androgen
synthesis
+ + Production of androgen within tumor cells
c. Change of AR specificity due to
mutations
+/- +
Stimulation by non-androgens (antagonists); androgen-re-
ceptor mutations; abnormal expression of AR co-factors
d. Ligand-independent AR
activation
- +
Growth factor functions as ligand (IL-6, IGF, EGF, KGF); 
alternative signaling pathways (STAT3, MAPK, Akt, cSrc); 
AR splicing variants ; abnormal expression of AR co-
factors
e. Bypassing the AR - -
Anti-apoptosis; neuroendocrine differentiation; alternative 
signaling pathways; methylation of the AR promoter
f. Proliferation of pre-existing
androgen-independent tumor cells
- - Malignant epithelial stem cells
AR, androgen receptor
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AR gene of LNCaP cell line contains one mutation at 
codon 877 (Thr to Ala). The growth of LNCaP cells is 
stimulated in vitro by a wide variety of substances, in-
cluding androgens, estrogens, progesterone and several 
anti-androgens, indicating the broadened ligand respon-
siveness of AR mutants.29) 
　Sack et al. analyzed the crystallographic structures of 
the AR ligand-binding domain (LBD). The AR LBD is 
monomeric, possibly because of the extended C termi-
nus of the AR, which lies in a groove at the dimerization 
interface. The binding of the natural ligand, DHT, by 
the mutant LBD involves interactions with the same 
residues as in the wild-type receptor, with the excep-
tion of the side chain of threonine 877, which is an ala-
nine residue in the mutant. This structural difference in 
the binding pocket may explain the ability of the mu-
tant AR found in LNCaP cells (T877A) to accommodate 
progesterone and other ligands that the wild-type re-
ceptor cannot.30) The same mutation was the most fre-
quently found in clinical practice, especially within the 
patients who underwent maximal androgen blockade 
using flutamide.31) 
　Given that certain mutations can alter AR ligand 
specificity, AR mutations might play a key role in ‘an-
ti-androgen withdrawal syndrome’.32,33) This phenome-
non occurs in a subset of patients with castration-resis-
tant progression. The cessation of anti-androgen medi-
cation improves the symptoms and the serum PSA 
levels decrease, suggesting that the anti-androgen acts 
agonistically in the tumor cells to promote growth. Our 
previous study found that in two of four patients who 
experienced improvement after anti-androgen with-
drawal, AR mutations had occurred during anti-andro-
gen treatment.#32) These mutations were identical to 
that in LNCaP cells (T877A), and were not detected in 
untreated tumors. Furthermore, it is known that AR 
mutations such as Trp741Cys or Trp741Leu are acti-
vated by bicalutamide.#34)
D. Ligand-independent AR activation
　Androgen-independent activation of the AR mediates 
the castration-resistant progression of PCa in the ab-
sence of androgen. By using intracellular signaling 
pathways involving epidermal growth factor (EGF), in-
sulin-like growth factor-I (IGF-I), keratinocyte growth 
factor (KGF), interleukin-6 (IL-6) or HER2/neu, phos-
phorylation occurs in tyrosine residues or serine and 
threonine residues of the AR, and the AR is then acti-
vated without androgens.14,35～37) Several clinical investi-
gen-synthesizing enzymes and to maintain intratumoral 
androgens at concentrations capable of activating AR 
target genes and maintaining tumor cell survival.25) Dil-
lard et al. reported that established androgen-indepen-
dent PCa cell lines, PC3 and DU145, expressed the 
mRNA and proteins for scavenger receptor type B1 
(SRB1), steroidogenic acute regulatory (StAR) protein, 
cytochrome P450 cholesterol side chain cleavage 
(P450scc), 3beta-hydroxysteroid dehydrogenase (3be-
ta-HSD) and other enzymes involved in androgen bio-
synthesis. Moreover, the expression of all these proteins 
and enzymes was significantly higher in the andro-
gen-independent derivative of LNCaP PCa cells (C81) 
than in the androgen-dependent parental cell line (C33). 
　In serum-free cultures, the androgen-independent 
C81 cells secreted approximately five-fold more testos-
terone than C33 cells, as determined by immunoassays 
of the conditioned media. These cells could also directly 
convert radioactive cholesterol into testosterone, which 
was identified by thin layer chromatography. These re-
sults show that PCa cells in advanced stages of the dis-
ease could synthesize androgens from cholesterol, and 
hence, are not dependent upon testicular and/or adre-
nal androgens.26) In addition, Bertaglia et al. reported 
that serum testosterone levels lower than the currently 
adopted cutoff of 50 ng/dL have a prognostic role in 
patients with PCa receiving LHRH agonists, and are a 
promising surrogate parameter of LHRH agonist effica-
cy. Using a receiver operating characteristic curve, it 
was found that a testosterone value of 30 ng/dL offered 
the best overall sensitivity and specificity for the pre-
diction of death, with serum testosterone levels <30 ng/
mL associated with a significantly lower risk of death 
(adjusted HR, 0.45; P =0.034).27) It has been suggested 
that the maximal therapeutic efficacy in the treatment 
of CRPC will require agents capable of lowering the 
androgen level as much as possible, as well as inhibiting 
the intracrine steroidogenic pathways within the pros-
tate tumor microenvironment.25)
C. Mutations in the AR gene
　Mutations in the AR gene have been detected in 
about 10–20% of PCa specimens. The frequency of mu-
tations is generally higher in hormone-refractory, meta-
static tumors compared with untreated, lower-grade 
primary tumors.16) The initial drive to deal with AR 
gene mutations in PCa originated from a study of the 
LNCaP cell line, which was derived from a metastatic 
lesion of the lymph nodes of a patient with PCa.28) The 
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bodies specific to AR-V7 frequently detected the AR-V7 
protein in HRPC specimens, but rarely in hormone-näive 
PCa specimens. AR-V7 was localized in the nuclei of 
cultured PCa cells under androgen-depleted conditions, 
and was constitutively active, thus driving the expres-
sion of canonical androgen-responsive genes, as re-
vealed by both AR reporter assays and expression mi-
croarray analysis.44) In addition, CRPC positive for AR-
V7 did not respond to abiraterone or enzalutamide, and 
the patients showed significantly shorter survival.45) 
Therefore, AR variants may be explored as potential 
biomarkers and therapeutic targets for advanced PCa.
E. Bypassing the AR
1. Neuroendocrine differentiation (NED)
Neuroendocrine (NE) cells exist within prostatic ducts 
and acinar cells. These cells regulate the differentiation, 
proliferation and secretion of the prostate. The AR is 
not expressed in NE cells, and NED is thought to under-
lie one of the mechanisms by which cells undergo cas-
tration-resistant progression, because of its androgen-in-
dependence. In the majority of PCa cases, malignant NE 
cells were also found in tumor tissues to some extent. 
There is no clear definition of NED; however, a region 
is defined as having undergone NED if NE markers are 
positive by immunohistochemical staining. This is a ba-
sic feature of the prostate, regardless of whether it is 
benign or malignant. NE cells express certain peptide 
hormones or pro-hormones, which affect the target cells 
by endocrine, paracrine, autocrine and/or neuroendo-
crine transmission in an androgen-independent fash-
ion.46) Neuroendocrine markers can be measured in se-
rum or plasma samples. Chromogranin A, neuron-spe-
cific enolase and ProGRP have prognostic significance 
in PCa. Among these, serum chromogranin A is thought 
to be the most important, and the pretreatment serum 
levels of chromogranin A are associated with castra-
tion-resistant progression. 
　NED can be a therapeutic target.47) During endocrine 
therapy in metastatic PCa patients, the serum chro-
mogranin A values were not related to the serum PSA 
levels, and increased as the treatment periods increased. 
It has been suggested that the chromogranin A velocity 
has the potential to predict androgen-independent pro-
gression after endocrine therapy.48) In addition, we have 
reported that strong NED found in a prostate biopsy 
specimen at the time of castration-resistant progression 
correlates with significantly poorer survival.49) 
　The mechanisms underlying how NED induces cas-
gations have shown that the serum levels of the IL-6 
are significantly elevated in patients with castration-re-
sistant disease.38,39) These findings indicate that IL-6 is 
involved in the androgen-independent progression of 
PCa. 
　Ueda et al. demonstrated a mechanism of cross-talk 
between the IL-6 and AR signal transduction pathways 
in LNCaP human PCa cells. IL-6 induced several andro-
gen response element-driven reporters that were de-
pendent upon the AR, that increased the phosphoryla-
tion of mitogen-activated protein kinase (MAPK) and 
activated the AR N-terminal domain (NTD). Inhibitors 
of MAPK and JAK decreased the IL-6-induced phos-
phorylation of MAPK and activation of the AR N-termi-
nal domain (NTD). Immunoprecipitation and transacti-
vation studies showed a direct interaction between 
amino acids 234-558 of the AR NTD and STAT3 follow-
ing IL-6 treatment of LNCaP cells. The activation of the 
human AR NTD by IL-6 was mediated through MAPK 
and STAT3 signal transduction pathways in LNCaP 
PCa cells.37) 
　In clinical practice, significant suppression of serum 
IL-6, through inhibition of androgen-independent activa-
tion of the AR, is thought to be one of the mechanisms 
underlying the effects of dexamethasone therapy in 
PCa patients with progressive disease. The change in 
serum IL-6 levels was significantly associated with the 
response to dexamethasone in the treatment of 
CRPC.40～42)
　Recently, altered AR splicing patterns have been 
identified as a mechanism of PCa progression and resis-
tance to ADT. Several studies have described the syn-
thesis of alternatively spliced transcripts encoding trun-
cated AR isoforms that lack the ligand-binding domain, 
which is the ultimate target of androgen depletion. 
Many of these truncated AR isoforms function as con-
stitutively active, ligand-independent transcription fac-
tors that can support androgen-independent expression 
of AR target genes, as well as the androgen-indepen-
dent growth of PCa cells.43) Luo’s group reported seven 
AR variant transcripts lacking the reading frames for 
the ligand-binding domain due to the splicing of “intron-
ic” cryptic exons to the upstream exons encoding the 
AR DNA binding domain. AR-V1 and AR-V7 mRNA 
showed an average 20-fold higher expression in CRPC 
(n=25) when compared with hormone-näive PCa (n=82; 
P<0.0001). Among the hormone-näive PCa cases, higher 
expression of AR-V7 predicted biochemical recurrence 
following surgical treatment (P=0.012). Polyclonal anti-
KOMIYA et al：Castration-resistant prostate cancer 15
the HGF/c-Met pathway may be of benefit when com-
bined with current androgen ablation treatment.53) 
　Yasuda et al. reported that HGF-related serum mark-
ers could be prognostic markers. The serum active 
HGF (AHGF) levels were increased in patients with 
stage D or D3 compared with stage B disease. In addi-
tion, there were significant differences in the serum 
AHGF levels between patients with well-differentiated 
and poorly-differentiated adenocarcinoma. Further-
more, the mean serum AHGF/THGF ratio in patients 
with stage D3 PCa was significantly higher than that in 
patients with stage B PCa.54) Hepatocyte growth factor 
activator inhibitor type-1 (HAI-1) inhibits hepatocyte 
growth factor activator and matriptase. The expression 
of HAI-1 detected by IHC in patients with PCa was 
significantly higher than that in the patients with a neg-
ative prostate biopsy. CRPC tumors exhibited signifi-
cantly lower HAI-1 expression than untreated metastat-
ic PCa. The PSA progression-free rate was worse in 
patients without HAI-1 expression than in those with 
positive HAI-1 expression.55)
3. The inhibition of apoptosis
Apoptosis, which is usually induced by ADT in PCa, is 
suppressed by the inactivation of tumor suppressor 
genes, or the activation of oncogenes and anti-apoptotic 
genes. Mutations in TP53 and PTEN are found in a 
subset of CRPC.56,57) Bcl-2 causes an anti-apoptotic effect 
by inhibiting the activation of caspase required for the 
induction of apoptosis. Furuya et al. reported the fre-
quency of bcl-2 protein expression using immunocyto-
chemical staining during the progression of human PCa 
from an androgen-sensitive non-metastatic phenotype 
to an androgen-independent metastatic phenotype. Five 
(17%) of the 30 lymph node metastases from pathologi-
cally disseminated D1 disease and 14 (52%) of 27 bone 
metastases from pathologically disseminated D2 disease 
expressed detectable bcl-2 protein. These data demon-
strate that there is a statistically significant (P<0.05) 
association between the expression of bcl-2 and the pro-
gression of human prostatic cancer cells to a metastatic 
phenotype.58) 
　Similarly, McDonnell et al., immunohistochemically 
evaluated androgen-dependent and androgen-indepen-
dent prostate carcinomas for bcl-2 expression. Bcl-2 was 
undetectable in 13 of 19 cases of androgen-dependent 
cancers. In contrast, androgen-independent cancers dis-
played diffuse, high levels of bcl-2 staining (P<0.01). 
These findings indicate that bcl-2 expression is aug-
tration-resistant progression in PCa are being investi-
gated. Wu and Huang showed that both the phosphati-
dylinositol 3-kinase-AKT-mammalian target of rapamy-
cin pathway and ERK are activated, but only the for-
mer is required for the NED of cells. Constitutively ac-
tive AKT promoted NED, and a dominant negative 
AKT inhibited it. The activation of AKT by IGF-1 led 
to NED, and the NED induced by epinephrine required 
AKT activation. The authors of that study also showed 
that the AKT pathway is likely responsible for the 
NED of DU145 cells.50) 
　Neuroendocrine-derived parathyroid hormone-relat-
ed protein (PTHrP)-mediated signaling through the epi-
dermal growth factor receptor (EGFR) and Src path-
ways contributes to the phenotype of advanced PCa by 
reducing the AR protein turnover. PTHrP-induced ac-
cumulation of the AR depended on the activity of Src 
and EGFR and subsequent phosphorylation of the AR 
on Tyr (534). PTHrP-induced tyrosine phosphorylation 
of the AR resulted in reduced AR ubiquitination and 
interaction with the ubiquitin ligase COOH terminus of 
Hsp70-interacting protein. These events resulted in in-
creased accumulation of the AR, and thus enhanced the 
growth of PCa cells at low levels of androgen.51)
2. The HGF/cMET pathway
Hepatocyte growth factor (HGF) is a ligand of c-MET. 
This ligand-receptor system promotes proliferation, mi-
gration, invasion, metastasis and anti-apoptosis effects 
in cancer cells, including PCa. HGF is expressed in stro-
mal cells, and its receptor, c-MET, is expressed in an-
drogen-independent PCa cells (PC-3 and DU145), but 
not in androgen-dependent PCa cells (LNCaP).51) There 
is a potential link between androgen signaling and 
c-Met expression in PCa cells. For example, it is known 
that the AR represses the expression of c-Met in a li-
gand-dependent manner. The AR controls HGF/c-MET 
and ADT upregulates this system. Sp1 induces the 
transcription of c-Met, and the AR can repress the 
Sp1-induced transcription in PCa cells. The AR inter-
feres with the interaction between Sp1 and the func-
tional Sp1 binding site within the c-Met promoter. The 
repressive role of androgen signaling on c-Met expres-
sion was confirmed in PCa xenografts. Although the 
currently used androgen ablation therapies can repress 
the expression of growth-promoting genes that are ac-
tivated by the AR, it may also attenuate the repressive 
role of AR on c-Met expression. Therefore, the introduc-
tion of therapeutic strategies to inhibit the activation of 
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would rarely expect to encounter this kind of PCa in 
clinical practice.
III. Treatment of CRPC
The agents for CRPC/HRPC approved by the U.S. Food 
and Drug Administration are summarized in Tables 2 
and 3. The endpoints are largely classified as quality of 
life or palliation and survival.
A. Agents to improve the QOL
　Tannock et al. reported the results of thirty-seven 
patients with symptomatic bone metastases from pros-
tate cancer that had progressed following earlier treat-
ment with estrogens and/or orchidectomy, who were 
treated with low-dose prednisone (7.5 to 10 mg daily).65) 
Thirty-eight percent of these patients showed improve-
ment in indices used to assess pain at one month after 
starting prednisone. The major findings of that study 
were that: (1) low-dose prednisone may lead to pain re-
lief in some patients with advanced PCa. (2) The pain 
relief was associated with suppression of adrenal andro-
gens. (3) Measures of pain and quality of life can be used 
to assess the possible benefits of systemic therapy in 
patients with metastatic PCa.
　Tannock et al. also reported the results of a study 
comparing chemotherapy with mitoxantrone plus pred-
nisone or prednisone alone for symptomatic hormone-re-
sistant PCa in a Canadian randomized trial with pallia-
mented following androgen ablation, and is correlated 
with the progression of PCa from androgen dependence 
to androgen independence.59) Bcl-2 has previously been 
addressed as a therapeutic target in hormone-refracto-
ry PCa, and antisense therapy was also developed for 
the MDM2 oncogene, which regulates p53 and various 
other molecules associated with cancer.60～62) In addition, 
the effects of Bcl-xL of the Bcl-2 family with regard to 
suppressing apoptosis are very strong. Enforced ex-
pression of the Bcl-xL gene dramatically increased the 
cell proliferation in vitro and promoted xenograft tumor 
growth in vivo. Bcl-xL overexpression significantly in-
creased the expression of cyclin D2, which might be 
responsible for Bcl-xL-induced cell proliferation and tu-
mor growth. Therefore, androgen controls Bcl-xL ex-
pression via the AR, and the increased Bcl-xL expres-
sion plays a versatile role in the castration-resistant 
progression of PCa.63)
F. Proliferation of pre-existing androgen-independent 
tumor cells
　Coffey and Isaacs at Johns Hopkins University postu-
lated that the androgen independence of PCa was due 
to a selective growth advantage of preexisting hor-
mone-independent clonal populations of preexisting, 
hormone-independent stem cells. This mechanism is 
likely to be completely independent of androgen- and 
AR-dependent growth stimulation.64,65) However, one 
Table 2. Agents used for palliation in CRPC/HRPC approved by the U.S. Food and Drug Administration
Agents for
palliation
Year Endpoint Indication
Estramustine 1981 QOL
Indicated for the palliative treatment of patients with metastatic and/or progressive 
carcinoma of the prostate
Prednisone (1989) QOL
Mitoxantrone + 
corticosteroids
1996 QOL Pain related to advanced hormone-refractory prostate cancer
Strontium 89 
chloride
1993 QOL Palliation of painful bone metastases
Samarium 153 1997 QOL Relief of osteoblastic bone pain in cancer patients.
Phosphorus 32 QOL Seldom used -- 89Sr and 153Sm are considered safer agents.
Zoledronic acid 2003 QOL/SRE
The treatment of hypercalcemia of malignancy.
The treatment of patients with documented bone metastases from solid tumors, in 
conjunction with standard antineoplastic therapy. Prostate cancer should have pro-
gressed after treatment with at least one hormonal therapy.
Denosumab 2010 QOL/SRE
The prevention of skeletal-related events (SREs) in patients with bone metastases 
from solid tumors
Denosumab 2011 QOL/SRE
A treatment to increase bone mass in patients who are at high risk of fractures from 
receiving androgen deprivation therapy (ADT) for nonmetastatic prostate cancer 
CRPC, castration-resistant prostate cancer; HRPC, hormone-refractory prostate cancer; QOL, quality of life; SRE, 
skeletal-related event
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dence of a therapeutic response to strontium-89 com-
pared with only a limited placebo effect (P<0.01).
　Zoledronic acid and denosumab are agents that can 
suppress osteoblast and skeleton-related events (SREs), 
defined as pathological fractures, spinal cord compres-
sion, bone pain requiring palliative radiotherapy and 
orthopedic surgery. SREs deteriorate the patients’ qual-
ity of life. Saad et al. studied the effects of a new bis-
phosphonate, zoledronic acid, which blocks bone de-
struction, on the skeletal complications in PCa patients 
with bone metastases.68) In that study, a greater propor-
tion of patients who received placebo had SREs than 
those who received zoledronic acid at a dose of 4 mg 
(44.2% versus 33.2%; P=0.021). The median time to first 
SRE was 321 days for patients who received placebo, 
and was not reached for patients who received zole-
dronic acid (P=0.011 versus placebo). The pain and anal-
gesic scores increased more in patients who received 
placebo than in patients who received zoledronic acid, 
but there were no significant differences in disease pro-
gression. The infusion of 4 mg of Zoledronic acid every 
three weeks reduced SREs in PCa patients with bone 
metastases.
　Fizazi et al. conducted a randomized, double-blind 
study to compare denosumab and zoledronic acid for 
the treatment of bone metastases in males with CRPC.68) 
Denosumab is a human monoclonal antibody against 
RANKL; it also inhibits osteoclast-mediated bone de-
struction. The median time to first on-study SRE was 
20.7 months with denosumab, compared with 17.1 
tive endpoints.66) Palliative responses were observed in 
23 of 80 patients (29%) who received mitoxantrone plus 
prednisone, and in 10 of 81 patients (12%) who received 
prednisone alone (P=0.01). The duration of palliation 
was longer in patients who received chemotherapy (me-
dian, 43 and 18 weeks; P<0.0001, log-rank). There were 
no significant differences in the PSA response or overall 
survival between the groups. Most responding patients 
had an improvement in quality-of-life scales and a de-
crease in the serum PSA level. Based on these studies, 
mitoxantrone plus prednisone and prednisone alone 
were still used as controls in recent randomized con-
trolled trials for the treatment of CRPC. However, mi-
toxantrone is not approved for the treatment of PCa in 
Japan.
B. Bone-targeted therapies
　Strontium-89 chloride, Samarium-153 and Phospho-
rus-32 are radioactive agents used to relieve painful 
bone metastases. Strontium-89 acts as calcium mimic 
and is absorbed by the bone metastases. Lewington et 
al. conducted a prospective, randomized, double-blind 
crossover study to examine the efficacy of strontium-89 
in pain palliation in patients with advanced prostate 
cancer metastatic to bone.67) Dramatic improvement, 
some improvement, no improvement/deterioration 
were found in four, four and four patients in the stron-
tium-89 injection group and zero, three and eleven pa-
tients in the placebo group. A statistical comparison 
between placebo and strontium-89 showed clear evi-
Table 3. Agents with a survival benefit in CRPC/HRPC patients approved by the U.S. Food and Drug Administration
Agents Year Endpoint Indication
Docetaxel 2004 OS
HRPC: with prednisone in androgen-independent (hormone-refractory) metastatic prostate 
cancer
Cabazitaxel 2010 OS
A microtubule inhibitor used in combination with prednisone, indicated for the treatment 
of patients with metastatic HRPC previously treated with a docetaxel-containing regimen
Sipuleucel-T 2010 OS
An autologous cellular immunotherapy indicated for the treatment of asymptomatic or 
minimally symptomatic metastatic CRPC/HRPC
Abiraterone
acetate
2011 OS
A CYP17 inhibitor indicated for use in combination with prednisone for the treatment of 
patients with metastatic CRPC who have received prior chemotherapy containing 
docetaxel
Abiraterone
acetate
2012 OS/rPFS
Used with prednisone for metastatic castration-resistant prostate cancer before chemo-
therapy
Enzalutamide 2012 OS
An androgen receptor inhibitor indicated for the treatment of patients with metastatic 
CRPC who have previously received docetaxel 
Radium 223
dichloride
2013 OS
Used for the treatment of patients with CRPC, symptomatic bone metastases and no 
known visceral metastatic disease
Enzalutamide 2014 OS/rPFS The treatment of patients with metastatic CRPC (who have not received chemotherapy)
CRPC, castration-resistant prostate cancer; HRPC, hormone-refractory prostate cancer; QOL, quality of life; OS, overall sur-
vival; rPFS, radiographic progression-free survival
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compared with mitoxantrone and prednisone, provided 
support for using this approach in patients with meta-
static, androgen-independent prostate cancer.
　In 2010, another taxane, cabazitaxel, became avail-
able.71) Cabazitaxel is a novel tubulin-binding taxane 
drug with antitumor activity in docetaxel-resistant can-
cers. In the TROPIC study, de Bono et al. reported the 
results of a comparison of the efficacy and safety of 
cabazitaxel plus prednisone with those for mitoxan-
trone plus prednisone in patients with metastatic CRPC 
with progressive disease after docetaxel-based treat-
ment. The median survival was 15.1 months in the 
cabazitaxel group and 12.7 months in the mitoxantrone 
group (as a control). The hazard ratio for death of the 
patients treated with cabazitaxel compared with those 
taking mitoxantrone was 0.70 (p<0.0001). Treatment 
with cabazitaxel plus prednisone had significant clinical 
antitumor activity, improving the overall survival in pa-
tients with metastatic CRPC whose disease has pro-
gressed during or after docetaxel-based therapy. Two 
ongoing trials (FIRSTANA and PROSELICA) are now 
being performed to evaluate two different doses of 
cabazitaxel (20 and 25 mg/m2) in the pre- and post-
docetaxel settings to assess whether dose reduction, 
often required because of myelotoxicity, affects the 
therapeutic response.72)
　One immunotherapy, sipuleucel-T, was approved 
based on the results of the IMPACT study in 2010.73) 
Sipuleucel-T is an active cellular immunotherapy, a 
type of therapeutic cancer vaccine, consisting of autolo-
gous peripheral blood mononuclear cells, including anti-
gen-presenting cells, that have been activated ex vivo 
with a recombinant fusion protein (PA2024). PA2024 
consists of a prostate antigen, prostatic acid phospha-
tase, that is fused to granulocyte-macrophage colo-
ny-stimulating factor, an immune cell activator. Sipuleu-
cel-T has shown evidence of efficacy for reducing the 
risk of death among patients with metastatic CRPC. In 
the sipuleucel-T group, there was a relative reduction 
of 22% in the risk of death compared with the placebo 
group (hazard ratio, 0.78; P=0.03). This reduction repre-
sented a 4.1-month improvement in median survival 
(25.8 months in the sipuleucel-T group vs. 21.7 months 
in the placebo group). Among patients with PSA assess-
ments after baseline, reductions of at least 50% on two 
visits at least four weeks apart were observed in eight 
of 311 patients (2.6%) in the sipuleucel-T group, com-
pared with two of 153 patients (1.3%) in the placebo 
group. The use of sipuleucel-T prolonged the overall 
months with zoledronic acid (hazard ratio 0.82; P=0.0002 
for non-inferiority; P=0.008 for superiority). More events 
of hypocalcaemia occurred in the denosumab group 
(13%) than in the zoledronic acid group (6%, P<0.0001). 
Osteonecrosis of the jaw occurred infrequently in both 
groups (2% vs. 1%; P=0.09). Therefore, denosumab was 
better than zoledronic acid for the prevention of skele-
tal-related events, and potentially represents a novel 
treatment option for patients with bone metastases 
from CRPC.
C. Agents to improve the overall survival
　Docetaxel was the first agent demonstrated to pro-
long the overall survival in CRPC patients. This agent 
was approved in 2004 and still plays an important role 
in the treatment of CRPC. The mechanism of action of 
taxanes seems to involve not only microtubule stabiliza-
tion and inhibition of tubulin function, but also both AR 
nuclear localization and signaling inhibition. There were 
two important trials that established the efficacy of 
docetaxel. One was TAX 327 conducted by Tannock et 
al.69) They showed that, compared with the patients in 
the mitoxantrone group, those in the group given 
docetaxel every three weeks had a hazard ratio for 
death of 0.76 (P=0.009 by the stratified log-rank test) 
and those given weekly docetaxel had a hazard ratio for 
death of 0.91 (P=0.36). The median survival was 16.5 
months in the mitoxantrone group, 18.9 months in the 
group given docetaxel every three weeks and 17.4 
months in the group given weekly docetaxel. Among 
these three groups, 32%, 45% and 48% of patients had 
at least a 50% decrease in the serum PSA level, respec-
tively (P<0.001 for both comparisons with mitoxan-
trone). When given with prednisone, docetaxel (given 
every three weeks) led to superior survival and im-
proved response rates in terms of pain, the serum PSA 
level and the patient quality of life, as compared with 
mitoxantrone plus prednisone. 
　The other trial was the SWOG9916 trial conducted 
by Petrylak et al.70) The median overall survival was 
longer in the group given docetaxel and estramustine 
than in the group given mitoxantrone and prednisone 
(17.5 months vs. 15.6 months, P=0.02 by the log-rank 
test). PSA declines of at least 50% occurred in 50% and 
27% of patients, respectively (P<0.001), and objective 
tumor responses were observed in 17% and 11% of pa-
tients with bidimensionally measurable disease, respec-
tively (P=0.30). The improvement in median survival of 
nearly two months by docetaxel and estramustine, as 
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cation and impairs both DNA binding to androgen re-
sponse elements and the recruitment of coactivators. It 
is orally available and induced tumor regression in 
mouse models of CRPC. Of the first 30 patients treated 
with enzalutamide in a Phase I/II clinical trial, 13 of 30 
(43%) showed sustained declines (by >50%) in the serum 
concentrations of PSA. Then, the AFFIRM trial was 
conducted as a phase 3, double-blind, placebo-controlled 
trial by Scher in the setting of CRPC after chemothera-
py.79) The median overall survival was 18.4 months in 
the enzalutamide group versus 13.6 months in the pla-
cebo group (hazard ratio for death in the enzalutamide 
group, 0.63; P<0.001). The superiority of enzalutamide 
over placebo was shown with respect to all secondary 
endpoints, including the proportion of patients with a 
reduction in the PSA level by 50% or more (54% vs. 2%, 
P<0.001), the soft-tissue response rate (29% vs. 4%, 
P<0.001), the QOL response rate (43% vs. 18%, P<0.001), 
the time to PSA progression (8.3 vs. 3.0 months; hazard 
ratio, 0.25; P<0.001), the radiographic progression-free 
survival (8.3 vs. 2.9 months; hazard ratio, 0.40; P<0.001) 
and the time to the first SRE (16.7 vs. 13.3 months; haz-
ard ratio, 0.69; P<0.001). Seizures were reported in five 
patients (0.6%) receiving enzalutamide. Therefore, en-
zalutamide was proven to significantly prolong the sur-
vival of patients with metastatic CRPC after chemo-
therapy, but is associated with a risk of seizures.
　In 2014, the results of the PREVAIL trial to develop 
new treatment options for patients with metastatic PCa 
who had not received chemotherapy, in whom the dis-
ease has progressed despite ADT were reported. This 
study was conducted by Beer et al. as a double-blind, 
phase 3 study.80) The co-primary endpoints were the 
radiographic progression-free survival and the overall 
survival, which were the same as in the COU-AA-302 
trial.76) The rate of radiographic progression-free surviv-
al at 12 months was 65% among patients treated with 
enzalutamide, compared with 14% among patients re-
ceiving placebo (81% risk reduction; hazard ratio in the 
enzalutamide group, 0.19; P<0.001). A total of 626 pa-
tients (72%) in the enzalutamide group, as compared 
with 532 patients (63%) in the placebo group, were alive 
at the data-cutoff date (29% reduction in the risk of 
death; hazard ratio, 0.71; P<0.001). The benefits of en-
zalutamide were shown with respect to all secondary 
endpoints, including the time until the initiation of cyto-
toxic chemotherapy (hazard ratio, 0.35), the time until 
the first SRE (hazard ratio, 0.72), the complete or partial 
soft-tissue response rates (59% vs. 5%), the time until 
survival among patients with metastatic CRPC, but no 
effect on the time to disease progression was observed, 
and the effects on PSA were limited.
　Abiraterone acetate is an oral steroid derivative used 
to suppress androgen production within the testes, ad-
renal glands and prostate by irreversibly inhibiting 
CYP17 (P450c17; C17, 20-lyase and 17α-hydroxylase). 
Abiraterone acetate affects both the classical and back-
door pathways of androgen biosynthesis.74) Using this 
agent, the serum testosterone level was reduced below 
the limit of detection. In the COU-AA-301 study, de 
Bono et al. evaluated whether abiraterone acetate pro-
longed the overall survival among patients with meta-
static CRPC who had received chemotherapy. The 
overall survival was longer in the abiraterone ace-
tate-prednisone group than in the placebo-prednisone 
group (14.8 months vs. 10.9 months; hazard ratio, 0.65; 
P<0.001). All secondary endpoints, including the time to 
PSA progression (10.2 vs. 6.6 months; P<0.001), progres-
sion-free survival (5.6 months vs. 3.6 months; P<0.001) 
and PSA response rate (29% vs. 6%, P<0.001), favored 
the treatment group.75)
　Furthermore, in the COU-AA-302 study, Ryan et al. 
reported the efficacy of abiraterone acetate in CRPC 
patients who had not received previous chemothera-
py.76) The co-primary endpoints were the radiographic 
progression-free survival and overall survival, which 
was based on a consensus among European experts in 
mCRPC to be appropriate primary endpoints for phase 
III clinical trials of CRPC.77) The median radiographic 
progression-free survival was 16.5 months with abi-
raterone-prednisone and 8.3 months with prednisone 
alone (hazard ratio for abiraterone-prednisone vs. pred-
nisone alone, 0.53; P<0.001). The overall survival was 
improved with abiraterone-prednisone (median not 
reached, vs. 27.2 months for prednisone alone; hazard 
ratio, 0.75; P=0.01) but did not cross the efficacy bound-
ary. Abiraterone-prednisone showed superiority over 
prednisone alone with respect to the time to initiation of 
cytotoxic chemotherapy, opiate use for cancer-related 
pain, PSA progression and the decline in performance 
status. Therefore, abiraterone acetate has a survival 
benefit for both chemotherapy-naïve and resistant 
CRPC patients.
　Enzalutamide (MDV3100) is a second generation 
non-steroidal anti-androgen developed by Tran et al. in 
2009.78) Enzalutamide binds to the AR with greater rel-
ative affinity than the clinically used anti-androgen bi-
calutamide, reduces the efficiency of its nuclear translo-
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Assessments of all main secondary efficacy endpoints 
also showed a benefit of radium-233 compared with pla-
cebo. Radium-223 was associated with low myelosup-
pression rates and few adverse events.
 
D. The current management of CRPC in the era of mul-
tiple agents that can prolong survival
　As shown above, during the past decade, multiple 
options for the treatment of CRPC that can achieve not 
only QOL improvement, but also survival benefit, have 
been introduced. Important clinical questions remain 
unclear; including which agent is the best, or what the 
best order or sequence is for these agents. Currently, 
there are no available data to prove the superiority of 
any of these new drugs compared to the others. Each 
study has had different patient eligibility criteria and 
background. Recently, updated clinical practice guide-
lines for CRPC recommend choosing agents based on 
the history of prior chemotherapy (docetaxel), the per-
formance status, state of metastasis and the patients’ 
symptoms.6,84,85) A summarized CRPC guideline from 
the American Urological Association is shown in Table 
4.84) The statements are presented in the guideline as 
Standards, Recommendations or Options. When suffi-
cient evidence existed, the body of evidence for a par-
ticular treatment was assigned a strength rating of A 
(high), B (moderate) or C (low). In the absence of suffi-
cient evidence, additional information was provided as 
Clinical Principles and Expert Opinions. There are 
PSA progression (hazard ratio, 0.17) and the rate of de-
cline of at least 50% in PSA (78% vs. 3%) (P<0.001 for all 
comparisons). Enzalutamide was also shown to signifi-
cantly decrease the risk of radiographic progression 
and death, and delayed the initiation of chemotherapy 
in patients with metastatic prostate cancer. The addi-
tional indication for use in the setting of CRPC before 
chemotherapy is just given to this agent in 2014.
　The newest agent approved for CRPC is radium-223. 
Radium-223 dichloride is a targeted alpha emitter that 
selectively binds to areas of increased bone turnover in 
bone metastases and emits high-energy alpha particles 
of short range (<100 μm).81) As a bone-seeking calcium 
mimetic, radium-223 is bound into newly formed bone 
stroma, especially within the microenvironment of os-
teoblastic or sclerotic metastases. The short path of the 
alpha particles also means that the toxic effects on adja-
cent healthy tissue, and particularly on the bone mar-
row, may be minimized.82) The ALSYMPCA study as-
sessed the efficacy and safety of radium-223 compared 
with placebo, in addition to the best standard of care, in 
patients with CRPC, bone metastases and no known 
visceral metastases, who had already received or were 
not eligible to receive docetaxel.83) Radium-223 signifi-
cantly improved overall survival compared to placebo 
(median, 14.0 months vs. 11.2 months; hazard ratio, 0.70; 
P=0.002). The updated analysis involving 921 patients 
confirmed the survival benefit of radium-223 (median, 
14.9 months vs. 11.3 months; hazard ratio, 0.70; P<0.001). 
Table 4 (a). A summary of the American Urological Association guideline for castration-resistant prostate cancer
Index 1 2 3
Symptoms - -, mild +
Metastasis - + +
Prior docetaxel - - -
P.S. (good) (good) good
Standard
(Level A, B)
abiraterone+P (A)
docetaxel (B), sipuleucel-T (B)
docetaxel (B)
Ra-223 (B)
Recommendation
(Level C)
observation with continued ADT (C) abiraterone+P (C)
Options
first-generation anti-androgens
(flutamide, bicalutamide, nilutamide) (C)
first generation androgen synthesis inhibitors
(ketoconazole+steroids) (C)
first-generation anti-androgens
(flutamide, bicalutamide, nilutamide) (C)
ketoconazole+steroids(C)
observation (C)
ketoconazole+steroids (C)
mitoxantrone (B)
radionuclide therapy (C)
Expert opinion
Should not offer,
recommendation
(Level C)
chemotherapy (C)
immunotherapy (C)
estramustine (C)
sipuleucel-T (C)
Expert opinion
against
P.S., performance status; P, prednisone; ADT, androgen deprivation therapy; Ra-223, radium-223
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